A clinical-stage oncology compound selectively targets drug-resistant cancers
Kaitlin Long, Debanjan Bhattacharjee, Samuel H. Newman-Stonebraker, Simon Suhr, Brandon Q. Mercado, Emily Scheib, Anthony Tighe, Luciano Romero, Sarah L. Thompson, Erin L. Sausville, Kristen M. John, Linda Julian, Sanat Mishra, Olaf Klingbeil, Punya Gupta, , Jason M. Sheltzer
This study reveals that PAC-1, a clinical-stage oncology compound, targets drug-resistant cancers by disrupting iron homeostasis and exploiting MDR1 expression to induce iron depletion.
bioRxiv · Nov 26, 2025 · PreprintCancer Biology